PTCE Pharmacy Connect | Pharmacy Times

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Best Practices for Management of Hyperlipidemia: A Focus on Guidelines and Patient Adherence Educational Objectives Examine best practices for optimizing medication adherence and treatment initiation in hypercholesterolemia management Explain patient education and counseling for managing hypercholesteremia Faculty: Joseph Saseen, PharmD, BCPS, BCACP, CLS Professor and Associate Dean for Clinical Affairs University of Colorado Anschutz Medical Campus Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora, Colorado   Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Executive Director, Ambulatory Pharmacy Services Grady Health System Atlanta, Georgia Joseph Saseen, PharmD, BCPS, BCACP, CLS, has the following financial relationships with commercial interests to disclose: Other Support (Lipid Monitoring Committee): Amgen (VESALIUS and OCEAN(a))   Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA, has the following financial relationships with commercial interests to disclose: Grant/Research Support: Novartis Consultant: Novartis, Regeneron   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-9999-25-069-H01-P. The activity is available for CE credit through March 31, 2026.   This activity is jointly provided by the University of Connecticut School of Pharmacy–Storrs and Pharmacy Times Continuing Education™, and is supported by an educational grant from Novartis Pharmaceuticals Corporation.   Please follow the link below to access this activity on PTCE and claim CE credit: www.pharmacytimes.org/hyperlipidemiapodcast

Educational Objectives Review recent clinical updates of RET inhibitors and how they fit into the treatment paradigm for non‒small cell lung cancer Identify and manage adverse effects of RET inhibitors to ensure patient safety and improve adherence   Faculty Lauren Ledbetter, PharmD, BCOP Clinical Pharmacy Specialist, Thoracic Medical Oncology The James Cancer Hospital at The Ohio State University Columbus, Ohio   Moderator Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Clinical Pharmacy Manager University of Kansas Cancer Center Division of Hematologic Malignancies & Cellular Therapeutics   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-24-304-H01-P. The activity is available for CE credit through October 31, 2025.   This activity is supported by an educational grant from Rigel Pharmaceuticals, Inc.

Educational Objectives Review challenges that impact optimal treatment of skin barrier dysfunction in patients with acne who are seeking OTC care List strategies to individualize patient care and improve recommendations for patients with acne experiencing skin barrier dysfunction Faculty: Robin Laird Patient Advocate Los Angeles, California   Mary Barna Bridgeman, PharmD, BCPS, BCGP Clinical Professor Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey Piscataway, New Jersey   Internal Medicine Pharmacist Robert Wood Johnson University Hospital-New Brunswick New Brunswick, New Jersey Mary Barna Bridgeman, PharmD, BCPS, BCGP, has no relevant financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Liza Patel, PharmD, RPh; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose. An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.05 CEU) under the ACPE universal activity numbers 0290-0000-24-128-H01-P and 0290-0000-24-128-H01-T. The activity is available for CE credit through April 29, 2025. This activity is supported by an educational grant from CeraVe. 

  Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Title: Challenges in Treatment of Desmoid Tumors and Managed Care Solutions Educational Objectives • Recall the key characteristics of desmoid tumors (DT), including presentation, frequency, genetic mutations, development, and outlook for individual patients • Outline practical solutions to improve managed care-driven communication with health care providers and address the clinical and financial burden of unresectable, recurrent DT Moderator: Laura Bobolts, PharmD, BCOP Senior Vice President of Clinical Strategy and Growth OncoHealth Plantation, Florida   Faculty: Christy Harris, PharmD, BCOP, FHOPA     Clinical Pharmacy Specialist                                                                Dana-Farber Cancer Institute Associate Professor Massachusetts College of Pharmacy and Health Sciences Boston, Massachusetts   Christy Harris, PharmD, BCOP, FHOPA and Laura Bobolts, PharmD, BCOP have no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-23-421-H01-P. The activity is available for CE credit through February 28, 2024. This activity is supported by an educational grant from SpringWorks Therapeutics.  

To claim CE credit for this activity, please follow this link: www.pharmacytimes.org/atopic-derm-podcast-630 Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Educational Objectives Review patient barriers that impact optimal treatment of patients with atopic dermatitis (AD) who are seeking OTC care List strategies to individualize patient care and improve recommendations for AD Moderator: Mary Bridgeman, PharmD, BCPS, BCGP Clinical Professor Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey Piscataway, New Jersey   Internal Medicine Clinical Pharmacist Robert Wood Johnson University Hospital New Brunswick, New Jersey   Faculty & Caregiver: Ashley Ellis, PharmD, MBA, CDECS ImPAcT Director & Assistant Professor The University of Tennessee Health Science Center Department of Clinical Pharmacy and Translation Science College of Pharmacy Memphis, Tennessee   Mary Bridgeman, PharmD, BCPS, BCGP has no financial relationships with commercial interests to disclose. Ashley Ellis, PharmD, MBA, CDECS, has the following financial relationships with commercial interests to disclose: Grant/Research Support: Researcher AHRQ “Tennessee Heart Health Network” funding in form of salary release dollars Consultant: Global Parents for Eczema Research, Continuing Education Alliance, McGraw Hill   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-23-268-H01-P and 0290-0000-23-268-H01-T. The activity is available for CE credit through June 30, 2024. This activity is supported by an educational grant from CeraVe and La Roche-Posay. Brought to you in partnership with the National Eczema Association.

Educational Objectives Outline the place in therapy for targeted therapies based on patient-specific factors and subtype of early-stage breast cancer Recognize methods to improve patient treatment selection while mitigating toxicities in patients with early-stage breast cancer Faculty: Allison R. Butts, PharmD, BCOP Pharmacist Manager, Oncology Breast Oncology Clinical Pharmacy Specialist Acute Care Pharmacy Services UK HealthCare- Markey Cancer Lexington, Kentucky   Director, PGY2 Oncology Residency Program UK HealthCare Lexington, Kentucky Allison R. Butts, PharmD, BCOP, has the following financial relationships with commercial interests to disclose: Consultant: AstraZeneca; BeyondSpring (one-time advisory boards) Moderator: Laura R. Bobolts, PharmD, BCOP SVP, Clinical Strategy and Growth OncoHealth Laura R. Bobolts, PharmD, BCOP, has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-23-239-H01-P. The activity is available for CE credit through May 31, 2024. This activity is supported by independent medical educational grants from AstraZeneca; Merck & Co., Inc.; Puma Biotechnology Inc., and Lilly.

Educational Objectives Recall the pathophysiology and clinical manifestations of Duchenne muscular dystrophy (DMD), as well as the burden of DMD and its impact on patient quality of life List the latest updates for the safety and efficacy data of new and approved disease-modifying therapies in the treatment of DMD   Faculty: Amanda Hickman, PharmD, MPH, MSCS Central Support Pharmacist – Neuro/Psych/Sleep Trellis Rx Atlanta, Georgia   Moderator: Jessica L. Kerr, PharmD, CDCES Associate Dean – Office Professional and Student Affairs Professor/Clinical Pharmacist Southern Illinois University Edwardsville School of Pharmacy Edwardsville, Illinois   Amanda Hickman, PharmD, MPH, MSCS, and Jessica L. Kerr, PharmD, CDCES, have no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEU) under the ACPE universal activity number 0290-0000-22-613-H01-P. The activity is available for CE credit through December 22, 2023.   This activity is supported by an educational grant from Sarepta Therapeutics.

Educational Objective: Outline various challenges and uncertainties affecting the optimization of treatment with novel immunotherapeutic modalities for relapsed/refractory diffuse large B-cell lymphoma.   Faculty: Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist - Hematology University of Michigan Rogel Cancer Center Ann Arbor, Michigan   Moderator: Laura R. Bobolts, PharmD, BCOP SVP, Clinical Strategy and Growth OncoHealth Plantation, Florida   Victoria Nachar, PharmD, BCOP & Laura R. Bobolts, PharmD, BCOP, have no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-22-611-H01-P. The activity is available for CE credit through December 22, 2023.   This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc; Genmab; and AbbVie, Inc.

Educational Objectives Outline current guideline recommendations and strategies pharmacists can implement for the management of immune thrombocytopenia (ITP) Recall the efficacy and safety of emerging agents for the treatment of ITP   Moderator: Anthony J. Perissinotti, PharmD, BCOP To claim CE credit for this activity, please visit the link below: https://www.pharmacytimes.org/courses/advances-in-the-treatment-of-immune-thrombocytopenia-strategies-for-optimizing-clinical-and-patient-outcomes Hematology Clinical Pharmacist Specialist Clinical Team Leader Hematology/Oncology Adjunct Clinical Assistant Professor University of Michigan – Michigan Medicine Ann Arbor, Michigan   Faculty: Lisa Charneski, PharmD, BCPS Assistant Dean for Academic Affairs Philadelphia College of Pharmacy Associate Professor of Clinical Pharmacy Department of Pharmacy Practice Saint Joseph’s University Philadelphia, Pennsylvania Anthony J. Perissinotti, PharmD, BCOP has the following relevant financial relationships with commercial interests to disclose: Consultant: AbbVie, BeiGene, Janssen Lisa Charneski, PharmD, BCPS, has no relevant financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Karleen Melody, PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.1 CEU) under the ACPE universal activity number 0290-0000-22-608-H01-P. The activity is available for CE credit through December 19, 2023.   This activity is supported by an educational grant from Rigel Pharmaceuticals, Inc.

The educational objectives are: • Review the pathophysiology of atopic dermatitis (AD) as well as the efficacy and safety data for topical JAK inhibitors that are approved and in development • Discuss the role of pharmacists as a part of the care team for patients with AD as well as the key counseling points and monitoring parameters   Faculty: Dennis Williams Moderator: Jamie McConaha